Company / Working Capital
Nurix Therapeutics, Inc. Working Capital History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$520.3M
FY2025
5-year range
$208.5M / $523.5M
FY2021-FY2025
Trend
-0.6%
vs FY2024
Sector context
#85 of 213
Health Care
What the data says
At $520M, Nurix Therapeutics, Inc.'s working capital ranks #85 of 213 in the Health Care sector. Working Capital has fluctuated over the past 7 years, ranging from $23M in FY2019 to $524M in FY2024.
Based on SEC 10-K filings.
$520M in FY2025 with a 5-year CAGR of +15.4%.
Improved from $209M to $520M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +28.1%
- 5-Year CAGR
- +15.4%
- 10-Year CAGR
- -
Sector benchmark
#85 of 213 in Health CareTop 40% of 213This company $520.3M Sector average $934.6M
▼
-44.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +15.4%, indicating consistent growth.
- In FY2025, working capital decreased 0.6% year-over-year.
- Ranks #85 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $520.3M | -0.6% |
| FY2024 | $523.5M | +151.0% |
| FY2023 | $208.5M | -15.8% |
| FY2022 | $247.8M | +1.2% |
| FY2021 | $244.9M | -3.6% |
| FY2020 | $253.9M | +993.6% |
| FY2019 | $23.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026